Copd

Edit

COPD patients' steps: Regular walking offers significant reduction in exacerbations

Pravda 09 Oct 2026

Regular walking may help reduce the frequency of moderate and severe exacerbations in patients with chronic obstructive pulmonary disease (COPD), regardless of air pollution levels.

Edit

Lupin launches fixed dose triple combo inhaler for COPD in India

The Hindu 07 Oct 2026

The product is an important addition to Lupin’s respiratory portfolio ....

Edit

Lupin launches fixed-dose triple combination inhaler for COPD in India

The Times of India 06 Oct 2026

It aims to benefit over 55 million people living with COPD across the country ... .

Edit

Could Laughter Help People With COPD Breathe Easier (MGC Diagnostics Corporation)

Public Technologies 06 Oct 2026

... presented at ERS 2026 explores laughter therapy as a potential breathing exercise for people living with COPD.

Edit

Your Postal Code Shouldn’t Determine Your COPD Care. In Canada, It Still Does.

Nasdaq Globe Newswire 05 Oct 2026

Lung Health Foundation’s new Canadian COPD Performance Index finds significant shortfalls in COPD care across the country ... .

Edit

COPD Flare-Up Symptoms: What to Watch for During Cold and Flu Season (Rotech Healthcare Holdings Inc)

Public Technologies 02 Oct 2026

) October 1, 2026 When you live with COPD, some coughing or shortness of breath may be part of an ordinary day ... [...] ... Disclaimer.

Edit

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation (Connect Biopharma Holdings Ltd)

Public Technologies 30 Sep 2026

). The text version of this document is not available ... Disclaimer ... (noodl. 134824120) .

Edit

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation (Form 8-K) (Connect Biopharma Holdings Ltd)

Public Technologies 30 Sep 2026

) Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation.

Edit

Kither Biotech Initiates Dosing of Patients in Phase 1b / 2a Study of KIT2014 in COPD

Nasdaq Globe Newswire 29 Sep 2026

Kither Biotech announces that it has dosed the first patients in its Phase 1b / 2a clinical study of KIT2014 in adults with moderate to severe COPD ... .

Edit

Signs of COPD

News & Record 28 Sep 2026

Darcy, a former smoker, blamed her chronic cough on a lingering cold. She noticed she was getting winded just climbing stairs and started cutting back on everyday activities without even realizing why ... .

Edit

COPD Outreach service at Sligo University Hospital suspended since August as key post lies vacant

Irish Independent 23 Sep 2026

There was a 78% reduction in admissions and an estimated €253,000 net savings over an 11 month study period when the service was operational ....

Edit

Chronic Obstructive Pulmonary Disease (COPD) Market to reach USD 72.55 Billion by 2035 at 8.50% CAGR

The Daily Record - Dunn 19 Sep 2026

COPD Market to Surge from USD 32.10 Billion in 2025 to USD 72.55 Billion by 2035-By Rising Disease Prevalence, ....

Edit

VA Research Wrap Up: New findings on TBI, COPD and skin cancer (US Department of Veterans Affairs)

Public Technologies 19 Sep 2026

) VA's Office of Research and Development recently published three News Briefs highlighting TBI resiliency, a COPD rehab program and skin cancer treatment ... [...] ... Disclaimer ... (noodl.

Edit

First biologic treatment on the PBS for uncontrolled chronic obstructive pulmonary disease (COPD) (GlaxoSmithKline Australia Pty Ltd)

Public Technologies 13 Sep 2026

NUCALA is indicated as an add-on maintenance treatment for adult patients with uncontrolled COPD with raised blood eosinophils on stable inhaler triple therapy (or, where clinically required, an equivalent regimen) ... COPD The Basics.

Edit

Altesa BioSciences Presents Novel Clinical Data Demonstrating Vapendavir Significantly Reduces Key Inflammatory Biomarkers in Rhinovirus-Challenged COPD Patients at the European Respiratory Society International Congress 2026 (Forbion Capital Partners Management Services BV)

Public Technologies 09 Sep 2026

The presentation, titled, "Inflammatory biomarkers are reduced by vapendavir treatment in rhinovirus-challenged COPD patients," was presented by Dr ... COPD patients in the study were ...

Podcasts:

Latest News for: copd

COPD patients' steps: Regular walking offers significant reduction in exacerbations

Lupin launches fixed dose triple combo inhaler for COPD in India

Lupin launches fixed-dose triple combination inhaler for COPD in India

Could Laughter Help People With COPD Breathe Easier (MGC Diagnostics Corporation)

Your Postal Code Shouldn’t Determine Your COPD Care. In Canada, It Still Does.

COPD Flare-Up Symptoms: What to Watch for During Cold and Flu Season (Rotech Healthcare Holdings Inc)

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation (Connect Biopharma Holdings Ltd)

Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation (Form 8-K) (Connect Biopharma Holdings Ltd)

Kither Biotech Initiates Dosing of Patients in Phase 1b / 2a Study of KIT2014 in COPD

Signs of COPD

COPD Outreach service at Sligo University Hospital suspended since August as key post lies vacant

Chronic Obstructive Pulmonary Disease (COPD) Market to reach USD 72.55 Billion by 2035 at 8.50% CAGR

VA Research Wrap Up: New findings on TBI, COPD and skin cancer (US Department of Veterans Affairs)

First biologic treatment on the PBS for uncontrolled chronic obstructive pulmonary disease (COPD) (GlaxoSmithKline Australia Pty Ltd)

Altesa BioSciences Presents Novel Clinical Data Demonstrating Vapendavir Significantly Reduces Key Inflammatory Biomarkers in Rhinovirus-Challenged COPD Patients at the European Respiratory Society International Congress 2026 (Forbion Capital Partners Management Services BV)

Article Search

EXPLORE WN.com